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-Conotoxins Vc1.1 and Rg1A are peptides from the venom of marine Conus snails that are currently in development as a treatment for
neuropathic pain. Here we report that the 910 nicotinic acetylcholine receptor-selective conotoxins Vc1.1 and Rg1A potently and
selectively inhibit high-voltage-activated (HVA) calcium channel currents in dissociated DRG neurons in a concentration-dependent
manner. The post-translationally modified peptides vc1a and [P6O]Vc1.1 were inactive, as were all other -conotoxins tested. Vc1.1
inhibited the -conotoxin-sensitive HVA currents in DRG neurons but not those recorded from Xenopus oocytes expressing CaV2.2,
CaV2.1, CaV2.3, or CaV1.2 channels. Inhibition ofHVA currents byVc1.1was not reversed by depolarizing prepulses butwas abolished by
pertussis toxin (PTX), intracellular GDPS, or a selective inhibitor of pp60c-src tyrosine kinase. These data indicate that Vc1.1 does not
interact with N-type calcium channels directly but inhibits them via a voltage-independent mechanism involving a PTX-sensitive,
G-protein-coupled receptor. Preincubation with a variety of selective receptor antagonists demonstrated that only the GABAB receptor
antagonists, [S-(R*,R*)][-3-[[1-(3,4-dichlorophenyl)ethyl]amino]-2-hydroxy propyl]([3,4]-cyclohexylmethyl) phosphinic acid hydro-
chloride (2S)-3[[(1S)-1-(3,4-dichlorophenyl)-ethyl]amino-2-hydroxypropyl](phenylmethyl) phosphinic acid andphaclofen, blocked the
effect of Vc1.1 and Rg1A on Ca2 channel currents. Together, the results identify CaV2.2 as a target of Vc1.1 and Rg1A, potentially
mediating their analgesic actions. We propose a novel mechanism by which -conotoxins Vc1.1 and Rg1A modulate native N-type
(CaV2.2) Ca
2 channel currents, namely acting as agonists via G-protein-coupled GABAB receptors.
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Introduction
Conotoxins are small peptides derived from the venom of the
Conus genus of predatory marine snails (Terlau and Olivera,
2004). Many conotoxins are highly selective antagonists of a di-
verse range of mammalian ion channels and receptors associated
with pain pathways. Thus, conotoxins are attractive as drug leads
for treating neuropathic pain. Previous studies have demon-
strated the analgesic potential of several different classes of cono-
toxins (Adams et al., 1999; Livett et al., 2004) and, most recently,
antagonists of neuronal nicotinic acetylcholine receptors
(nAChRs) have begun to show promise for the treatment of neu-
ropathic pain (Sandall et al., 2003; Lang et al., 2005; Satkunan-
athan et al., 2005; Vincler et al., 2006). The -conotoxins com-
petitively inhibit neuronal-type nAChRs (Dutton and Craik,
2001) with varying degrees of selectivity for different nAChR
subtypes (McIntosh et al., 1999).
-Conotoxin Vc1.1, which was first discovered using a PCR
screen of cDNAs from the venom ducts of Conus victoriae (San-
dall et al., 2003), contains two residues, Pro6 and Glu14, that are
post-translationally modified to hydroxyproline and
-carboxyglutamate, respectively, in the native peptide, desig-
nated vc1a (Jakubowski et al., 2004). Synthetic Vc1.1 lacking
these two modifications is a competitive antagonist of neuronal
nAChRs in bovine adrenal chromaffin cells (Clark et al., 2006)
and is potent at recombinant 910 nAChRs expressed in Xeno-
pus oocytes (Vincler et al., 2006;Nevin et al., 2007). Furthermore,
Vc1.1 and its post-translationally modified analogs vc1a,
[P6O]Vc1.1, and [E14]Vc1.1 have been reported to be equally
potent at inhibiting ACh-evoked currents mediated by 910
nAChRs (Nevin et al., 2007). Vc1.1 also antagonizes the nicotine-
induced increase in axonal excitability of unmyelinated C-fiber
axons in isolated segments of peripheral human nerves (Lang et
al., 2005). Blockade of nAChRs on unmyelinated peripheral
nerve fibers may have an analgesic effect on unmyelinated sym-
pathetic and/or sensory axons. Interestingly, synthetic vc1a,
which incorporates the modified residues, has been reported to
inhibit 910 (Nevin et al., 2007) but not 3-containing (Clark
et al., 2006) nAChRs expressed inXenopus oocytes and is inactive
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in two rat neuropathic pain assays (Livett et al., 2006). In con-
trast, Vc1.1 alleviates neuropathic pain in three rat models of
human neuropathic pain and accelerates the functional recovery
of injured neurons (Satkunanathan et al., 2005). -Conotoxin
Rg1A from Conus regius, which also selectively inhibits 910
nAChRs (Ellison et al., 2006), has similarly been shown to signif-
icantly reduce chronic constriction nerve injury-induced hyper-
algesia in rats (Vincler et al., 2006; Vincler and McIntosh, 2007).
Thus, although Vc1.1 is currently under development as a treat-
ment for neuropathic pain (Livett et al., 2004, 2006), its specific
receptor target has not been unequivocally identified. We show
here that Vc1.1 and Rg1A act by an unexpected mechanism not
reported previously for any conotoxin.
Materials andMethods
DRG neuron preparation. DRG neurons were enzymatically dissociated
from ganglia of 2- to 30-d-old Wistar rats according to standard proto-
cols. Rats were killed by cervical dislocation as approved by the Univer-
sity of Queensland Animal Ethics Committee, the spinal column was
hemi-segmented, and the spinal cord was removed. Ganglia were re-
moved and rinsed in cold HBSS (MultiCell). They were minced and
incubated in 1 mg/ml collagenase (type 2; 405 U/mg) (Worthington
Biochemical) in HBSS at 37°C for 30 min. After incubation, ganglia
were rinsed three times with warm (37°C) DMEM (Invitrogen) supple-
mented with 10% fetal calf serum and 1% penicillin/streptomycin, and
gently trituratedwith a fire-polished Pasteur pipette. Cells were plated on
glass coverslips, incubated at 37°C in 95% O2/5% CO2, and used within
4–48 h.
Electrophysiological methods. The external recording solution for rat
DRG neurons contained the following (in mM): 150 tetraethylammo-
nium (TEA)-Cl, 2 BaCl2, 10 D-glucose, and 10 HEPES, pH 7.3–7.4. Re-
cording electrodes were filled with an internal solution containing the
following (in mM): 140 CsCl, 1 MgCl2, 5 MgATP, 0.1 Na-GTP, 5 bis(2-
aminophenoxy)ethane-N,N,N,N-tetra-acetic acid (BAPTA)-Cs4, and
10 HEPES, pH 7.3–7.4, with CsOH, and had resistances of 1–2.5 M.
Membrane currents were recorded using the whole-cell configuration of
the patch-clamp technique with an Axopatch 200B amplifier (Molecular
Devices). Neurons were voltage clamped at a holding potential of 90
mV and Ba2 currents were elicited by step depolarizations, first to40
mV for 200 ms [for low-voltage-activated (LVA) currents] and then to
10 mV, from a holding potential of 50 mV, for 200 ms [for high-
voltage-activated (HVA) currents] at 10 s intervals. In a series of experi-
ments, BaCl2 was replaced by CaCl2. A voltage protocol using step depo-
larizations from70 to 0 mV was used when examining HVA currents
alone. Test potentials 150 ms in duration were applied every 20 s. To
construct current–voltage ( I–V) relationships, neurons were voltage
clamped at100 mV and voltage stepped from80 mV to50 mV in
10mV increments. Voltage-dependent inhibition was assessed by apply-
ing a prepulse to80mV for 20ms in duration before the test pulse. Leak
and capacitative currents were subtracted using a P/4 pulse protocol.
Currents were generated by a computer using pClamp 9.2 software (Mo-
lecular Devices), filtered at 2 kHz, and sampled at 8 kHz by the Digidata
1322A (Molecular Devices). Sampled data were stored digitally on a
computer for further analysis.
Oocyte preparation and recordings. Stage V–VI oocytes from Xenopus
laevis frogs were injected with either cRNA or cDNA encoding N- or
P/Q-type voltage-gated Ca2 channels (VGCCs), respectively. N-type
channels were examined in oocytes injected with 50 nl of solution con-
taining a mixture of cRNAs encoding rat CaV2.2 1B-b subunit (2.5–5
ng/cell) and rat 3 subunit (2.5–5 ng/cell) (cDNAs provided by Dr. D.
Lipscombe, Brown University, Providence, RI), with or without rabbit
21 subunit (2.5–5 ng/cell) (cDNAprovided byDr. F.Hofmann andDr.
N. Klugbauer, Technische Universita¨t Mu¨nchen, Munich, Germany).
L-type channels were examined in oocytes coinjected with rabbit Cav1.2
1C subunit (5 ng/cell) (cDNA provided by Dr. G. Zamponi, University
of Calgary, Calgary, Alberta, Canada) and auxiliary subunits 3 and 21
(see above). For experiments examining P/Q-type and R-type VGCCs,
the oocyte nucleus was injected first with cDNA encoding the rabbit
CaV2.11A (5 ng/cell) (cDNAprovided byDr. G. Zamponi) or rat Cav2.3
1E (4.5 ng/cell) (cDNA provided by Dr. G. Zamponi) subunit, respec-
tively, followed by cytoplasmic injection of auxiliary subunits 3 and
21 (see above). After injection, oocytes were kept at 18°C for 3–6 d
before use.
Before recording, oocytes were injected with 25 nl of 50mM BAPTA to
eliminate the endogenous Ca2-activated chloride conductance.
Depolarization-activated Ca2 channel currents were recorded using
Ba2 as a charge carrier and a two-electrode virtual ground voltage-
clamp circuit with a GeneClamp 500B amplifier (Molecular Devices).
The external bath solution contained the following (inmM): 85TEA-OH,
5 BaCl2, 5 KCl, and 10 HEPES, pH 7.4, with methanesulfonic acid. Dur-
ing recording, oocytes were constantly perfused with bath solution using
a gravity-fed perfusion system at a flow rate of1.5 ml/min. Electrodes
were filled with a solution containing 3 M KCl (0.5–1.0 M). Oocytes
were voltage clamped at a holding potential of80 mV and membrane
currents were elicited by 200ms step depolarization to 0mV (for CaV2.2)
or 20 mV (for CaV2.1) applied every 10 s. To construct I–V relation-
ships, cells were voltage-clamped at80mV and then stepped from80
mV to 50 mV in 10 mV increments. Data were low-pass filtered at 2
kHz, digitized at 10 kHz, leak subtracted online using a P/4 protocol,
and analyzed off-line.
Data analysis. Data were analyzed off-line using pClamp 9.2 software
(Molecular Devices). Peak Ba2 current amplitude in response to a de-
polarizing pulse was calculated and plotted against time to monitor sta-
bility of the recording. Generally, Ba2 current reached steady state
within 2–5min of initial recording, and any recordings that did not reach
steady state were discarded. Drugs were applied via perfusion in the bath
solution. Current amplitudes obtained in the presence of the drug were
normalized by dividing by the current amplitude obtained under control
conditions. Concentration–response relationships were obtained using
GraphPad Prism software by plotting normalized current amplitude as a
function of drug concentration and were fitted using a logistic equation.
Numerical data are presented as mean SEM.
Drugs and chemicals. CGP55845 (2S)-3[[(1S)-1-(3,4-dichlorophenyl)-
ethyl]amino-2-hydroxypropyl](phenylmethyl) phosphinic acid, CGP54626
[S -(R*,R*)][-3-[[1-(3,4-dichlorophenyl)ethyl]amino]-2-hydroxy
propyl]([3,4]-cyclohexylmethyl) phosphinic acid hydrochloride], and
pp60c-src peptide (521-533) corresponding to its C-terminal regulatory
domain were purchased from Tocris Bioscience. The peptide binds
pp60c-src at the Src homology 2 domain suppressing its tyrosine kinase
activity (Roussel et al., 1991). Phaclofen (3-amino-2-(4-chlorophenyl)
propylphosphonic acid was from BIOMOL. All other drugs were ob-
tained from Sigma-Aldrich and were prepared as concentrated stock
solutions which were then diluted in bath solution and applied via per-
fusion. The -conotoxins CVID andMVIIA were prepared as described
previously (Lewis et al., 2000). -Conotoxins Vc1.1, [P6O]Vc1.1,
[E14]Vc1.1, vc1a, RgIA, ImI, MII, BuIA and [A10L]PnIA, were synthe-
sized as reported previously (Gehrmann et al., 1999; Hogg et al., 1999;
Blanchfield et al., 2003; Clark et al., 2006, 2008; Jin et al., 2007) and
provided as a stock concentration in H2O of1 mM and used at a final
concentration of 0.1 nM to 1 M. Reduced Vc1.1 was prepared by incu-
bation with dithiothreitol (2 mM; 1 h; room temperature) or alkylated
with iodoacetamide in 0.1 M ammonium acetate buffer.
Results
910 nAChR-selective conotoxins, Vc1.1 and Rg1A, inhibit
voltage-gated Ca2 channel currents in rat DRG neurons
In an attempt to account for -conotoxin Vc1.1-induced analge-
sia and to elucidate the receptor target and mechanism of action,
the effects of the conotoxins, Vc1.1 and RgIA, were investigated
on voltage-gated Ca2 channel currents in rat DRG neurons.
Whole-cell Ca2 channel currents of rat DRG neurons are me-
diated by both LVA and HVA calcium channels (Scroggs and
Fox, 1992). The effect of Vc1.1 on Ca2 channel currents re-
corded from neonatal (2- to 10-d-old) rat DRG neurons was
initially assessed using a two-step protocol (see Materials and
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Methods). Vc1.1 (1 M) had no effect on LVA Ca2 channel
current amplitude elicited by voltage step from90 to40 mV
(97 12% of control, n 10). In the same cells, Vc1.1 inhibited
HVA Ca2 channel currents elicited by a 150 ms voltage step to
10 mV to 56.5 4.4% of control (n 10) (Fig. 1A,B). Vc1.1
only inhibited VGCC currents evoked by step depolarization
positive of40 mV, demonstrating the lack of effect of Vc1.1 on
LVA Ca2 channel currents (Fig. 1C). The effect of Vc1.1 on
HVA Ca2 channel currents was therefore assessed using a 150
ms step depolarization from a holding potential of either70 or
90mV to the test potential of either10 or 0mV at a frequency
of 0.05Hz, with 2mMBa2 as the charge carrier. Vc1.1 inhibition
ofHVACa2 channel currents developedwith a delay of2min
andmaximum inhibition occurred7min after the beginning of
the response, independent of the concentration of Vc1.1 (n 
74). Inhibition of HVACa2 channel currents by Vc1.1 was con-
centration dependent and the mean concentration–response
data gave an IC50 of 1.7 nM, with maximum inhibition to 57.8
3.8% of control occurring at 1 M (n 25) (Fig. 1D).
Vc1.1 (100 nM) inhibited VGCC currents in 75% of DRG
neurons (120 of 159) tested, including small (	20m),medium
(20–40 m), and large (40 m) neurons. Only a subset of
primary sensory DRG neurons are capsaicin sensitive (Szallasi
and Blumberg, 1999). There was no correlation between cell size
or capsaicin sensitivity and responsiveness to Vc1.1: 88%of small
cells (n  17), 71% of medium cells (n  51), and 76% of large
cells (n  91) responded to 10 nM Vc1.1; 5 of 8 capsaicin-
sensitive cells responded to Vc1.1 and 6 of 9 capsaicin-insensitive
cells responded to Vc1.1. Vc1.1 (100 nM) also inhibited VGCC
currents in 14 of 25 juvenile (11- to 20-d-old) and 4 of 6 adult
(28-d-old) rats (67.5  3.3% and 69.4  3.2% of control,
respectively).
Vc1.1 inhibition of VGCC currents was
not reversed during washout. However,
reapplication of Vc1.1 produced an equiv-
alent inhibition of HVA Ca2 channel
currents in other DRG neurons on the
same coverslip (n 5 sets), suggesting that
depolarization-induced Ca2 channel ac-
tivation is required for inhibition by
Vc1.1.
To further assess the dependence of
Vc1.1 inhibition on activation of HVA
Ca2 channel currents, we varied the fre-
quency and duration of the depolarizing
pulse in the presence of Vc1.1 (Fig. 2).
When the depolarization pulse was short-
ened to 15 ms with the frequency main-
tained at 0.05 Hz, 100 nM Vc1.1 inhibited
the current to only 88.4 3.3% of control
in all cells tested (n 24). However, when
the frequency of the 15 ms pulse was in-
creased to 0.1 Hz, the current was reduced
to 51.1 5.6% of control in all cells tested
(n 7) (Fig. 2A,B). Figure 2B also shows
the relative inhibition of Ba2 currents by
Vc1.1, using the standard depolarizing
pulse duration (150 ms) at both 0.05 Hz
and 0.1 Hz. The action of Vc1.1 does not
depend on a rise in intracellular divalent
cation, because the inhibition was also ob-
served with 2 mM Ca2 as the charge car-
rier. In 9 of 12 cells, Vc1.1 (100 nM) inhib-
ited the HVA Ca2 current amplitude to 61.4 5.2% of control
and was not reversible on washout (30min) (Fig. 2C). Further-
more, in fura-2-loaded DRG neurons, bath application of 1 M
Vc1.1 alone failed to elicit any increase in intracellular Ca2 con-
centration (n 14, data not shown).
Application of -conotoxin Rg1A (100 nM) also significantly
inhibitedHVACa2 channel currents in rat DRG neurons (11 of
14 responding cells) to 60.6 4.5% of control (Fig. 3A).
Post-translationally modified analogs of Vc1.1 and other -
conotoxins do not inhibit HVA Ca2 channel currents in
DRG neurons
The effects of post-translationallymodified analogs of Vc1.1were
examined onHVACa2 channel currents from ratDRGneurons
under the same conditions as Vc1.1. The native peptide, vc1a, did
not inhibit HVA Ca2 channel currents (100.0  4.8% of con-
trol, n  9); however, the same cells responded to Vc1.1 after
washout of vc1a (Fig. 3B,C). [P6O]Vc1.1 had no effect on HVA
Ca2 channel currents (103.7  7.2% of control, n  9) (Fig.
3C), whereas four of five cells from this test group subsequently
responded to Vc1.1 after washout of [P6O]Vc1.1. [E14]Vc1.1
was alsowithout effect (110.1 9.2%of control, n 7) (Fig. 3C),
but after its removal, all cells of this group tested with Vc1.1
showed a response (n  6). Both reduced Vc1.1 and alkylated
Vc1.1 (1M)werewithout effect onHVACa2 channel currents,
whereby the peak current amplitude was 98.8 7.1% of control
(n 10) and 104.9 11.4% of control (n 3), respectively (Fig.
3C).
The effects of other 4/7 -conotoxins (MII and [A10L]PnIa)
as well as the 4/3-conotoxin ImI, and the 4/4-conotoxin BuIA
were examined to ascertain whether inhibition of HVA Ca2
channel currents was a common characteristic of -conotoxins.
Figure 1. -Conotoxin Vc1.1 inhibits HVA calcium channels in rat DRG neurons. A, Superimposed traces of depolarization-
activated whole-cell calcium channel currents recorded using 2 mM Ba 2 as the charge carrier, elicited by a voltage step from a
holding potential of50 to 0mV in the absence (a) and presence (b) of 100 nM Vc1.1.B, Corresponding time course of inhibition
of peak Ba 2 current amplitude by 100 nM Vc1.1. Application of Vc1.1 is indicated by the bar. C, Plot of the I–V relationship for
peak Ba 2 currents in the presence (F) and absence (E) of Vc1.1 ( 100 nM) (n 16). D, Concentration–response curve for
inhibition of calcium channel currents in DRG neurons by Vc1.1. Data points represent mean SEM of normalized peak current
amplitude (n 8–25 cells per data point). Maximum inhibition was 42 3%with an IC50 of 1.7 nM.
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-Conotoxins ImI,MII, BuIA, and [A10L]PnIA applied at a con-
centration of either 100 nM or 1 M did not inhibit HVA Ca2
channel currents in DRG neurons (ImI, 95.5 5.1% of control,
n 7; MII, 93.2 1.6% of control, n 3; BuIA, 97.5 7.9% of
control, n 8; [A10L]PnIA, 91.0 4.1%of control, n 10) (Fig.
3C). Another conopeptide structurally related to the 4/7
-conotoxins, 	-TIA, an allosteric 1-adrenoreceptor antagonist
(Sharpe et al., 2003), also failed to inhibit HVA Ca2 channel
currents in DRG neurons when bath applied at 100 nM (n  6,
data not shown).
Vc1.1 inhibits the N-type component of HVA Ca2 channel
currents in DRG neurons
The selectiveN-typeCa2 channel blockers,-conotoxins CVID
and MVIIA, were applied to determine which component of the
whole-cell HVA Ca2 channel currents Vc1.1 inhibited in DRG
neurons. Bath application of 200 nM CVID reduced peak Ca2
channel current amplitude to 54.4  4.8% of control (n  6).
Application of 1 M Vc1.1 in the presence of CVID (200 nM)
produced no further reduction of theHVACa2 channel current
amplitude (51.7 5.1%of control,n 6) (Fig. 4A–C). Figure 4C
also shows the result of the converse experiment, that is, the
average response of cells to CVID (200 nM) after Vc1.1 (100
nM) application. Similar results were obtained with bath applica-
tion of 100 nM -conotoxin MVIIA, with 51.6  5.6% of the
current remaining after application of MVIIA and 50.4  0.1%
remaining in the presence of MVIIA and 100 nM Vc1.1 (n  5)
(data not shown).These data suggest that Vc1.1 inhibits the
N-type Ca2 channel in DRG neurons.
Action of Vc1.1 on expressed CaV2.1 and CaV2.2 channels
in oocytes
To assess whether Vc1.1 directly inhibits HVA Ca2 channels,
the  subunits of CaV2.1 (P/Q-type) and CaV2.2 (N-type) chan-
nels were expressed in Xenopus oocytes together with the auxil-
iary subunits 3/21 in the ratio 1:1:1. Bath application of 1 M
Vc1.1 did not significantly inhibit the Ba2 current amplitude for
oocytes expressing CaV2.2 channels (91.3 2.2% of control, n
8) (Fig. 5A,C). Analogous to CaV2.2-expressing oocytes, 1 M
Vc1.1 did not inhibit Ba2 currentsmediated byCaV2.1 channels
Figure 2. Vc1.1 inhibition of HVA calcium channel currents is use dependent. A, Represen-
tative time course of peak Ba 2 current amplitude recorded using a 15ms step depolarization
froma holding potential of80mV to a test potential of10mV at a frequency of either 0.05
or 0.1 Hz, as indicated, in the absence and presence of 100 nM Vc1.1.B, Bar graph of the relative
inhibition of HVA calcium channel currents by 100 nM Vc1.1 during a 15 ms depolarization at a
frequency of either 0.05 Hz (n 24) or 0.1 Hz (n 7 responsive cells of 7 tested), and a pulse
duration of 150ms and frequency of either 0.05 Hz (n 36 responsive cells of 50 tested) or 0.1
Hz (n 9 responsive cells of 12 tested).***p	 0.001 unpaired t test. C, Superimposed traces
of depolarization-activatedwhole-cell Ca 2 channel currents recorded using 2mMCa 2as the
charge carrier, elicited by a voltage step fromaholding potential of80 to 0mV in the absence
(a) and presence (b) of 100 nM Vc1.1.
Figure 3. Vc1.1 post-translationally modified analogs and other-conotoxins are without
effect on HVA calcium channel currents. A, Representative time course of peak Ba 2 current
amplitude in the presence of 100 nM RgIA. The holding potential was80 mV and the test
potential 10 mV. B, Representative time course of peak Ba 2 current amplitude in the
presence of 1M vc1a. C, Bar graph of relative inhibition of HVA calcium channel currents by
-conotoxins RgIA, ImI, [A10L]PnIA, MII, BuIA, alkylated Vc1.1, Vc1.1, and analogs. Vc1.1 (1
M) inhibited peak Ba 2 current amplitude in 25 of 30 cells tested. ***p 0.0001 compared
with control cells. Rg1A (100nM) inhibitedpeakBa 2 current amplitude in 11of 14 cells tested.
**p 0.0016 comparedwith control cells. Numbers in parentheses reflect the number of cells.
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(88.1  8.2% of control, n  4) (Fig. 5B,C). Raising the Vc1.1
concentration to 10 M similarly failed to inhibit the Ba2 cur-
rents mediated by either CaV2.1 or CaV2.2 channels expressed in
oocytes. A similar lack of effect of Vc1.1 on CaV2.3 (R-type) and
CaV1.2 (L-type) channels expressed in Xenopus oocytes was also
observed (data not shown). To investigate whether the auxiliary
subunits influence the sensitivity of recombinant Ca2 channels
to Vc1.1 (Yasuda et al., 2004), oocytes were injected with the
subunit combination CaV2.2/3 in a 1:1 ratio. Although cells ex-
pressing CaV2.2/3 elicited smaller Ca
2 channel currents than
those expressed by CaV2.2/3/21 channels, the Ba
2 current
amplitude was not appreciably changed (88  6.5% of control,
n  3) in the presence of 1 M Vc1.1 (Fig. 5C). Together, these
data indicate that Vc1.1 does not interact with either CaV2.1 (P/
Q-type) or CaV2.2 (N-type) channels directly, and that Vc1.1
modulation ofHVACa2 channel currents occurs via an indirect
mechanism.
Vc1.1 inhibits HVA Ca2 channel currents via a G-protein-
coupled receptor mechanism and src tyrosine kinase
The role of G-proteins in mediating Vc1.1 inhibition of HVA
Ca2 channel currents in DRG neurons was examined by replac-
ing GTP with GDPS, a nonhydrolyzable GDP analog, in the
intracellular recording solution. GDPS antagonized the effect of
Vc1.1 on Ca2 channel currents, with 96.8  4.5% of current
Figure4. Vc1.1 inhibitsN-type calciumchannels in ratDRGneurons.A, Superimposed traces
of depolarization-activated whole-cell Ba 2 currents under control conditions (a), in the pres-
ence of 200 nM -conotoxin CVID (b), and in the presence of CVID and 1 M Vc1.1 (c). B,
Representative time course of peak Ba 2 current amplitude in the presence of the selective
N-type Ca 2 channel inhibitor-conotoxin CVID followed by application of Vc1.1. The letters
a– c indicate the timepoints atwhich the superimposed currentswere obtained.C, Bar graphof
relative inhibition of HVA calcium channel currents by 200 nM CVID alone, after application of 1
MVc1.1 in the presence of CVID, in the presence of Vc1.1 alone, and after application of CVID in
the presence Vc1.1. Numbers in parentheses reflect the number of cells.
Figure5. Vc1.1 does not inhibit Ba 2 currents through recombinantN- andP/Q-type chan-
nels expressed in Xenopus oocytes. A, Superimposed current traces from an oocyte expressing
Cav2.21B-d/3/21 (N-type) calcium channels under control conditions (a) and in the pres-
ence of 1M Vc1.1 (b). B, Superimposed currents from an oocyte expressing Cav2.1 1E/3/
21 (P/Q-type) calcium channels in the absence (control) (a) and presence (b) of 1M Vc1.1.
C, Bar graph of relative current amplitude obtained for expressed N- and P/Q-type calcium
channels in the presence of 1M Vc1.1. Numbers in parentheses reflect the number of cells.
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remaining after addition of 100 nM Vc1.1 in the presence of
GDPS (n 15) (Fig. 6C).
These results suggest that Vc1.1 inhibits N-type Ca2 channel
currents in DRG neurons via a G-protein-coupled receptor
(GPCR) mechanism. Vc1.1 inhibition also persisted after appli-
cation of depolarizing prepulses to80mV, suggesting a voltage-
independent inhibitory pathway (n 7) (Fig. 6C). Incubation of
cells in medium containing 3 g/ml pertussis toxin (PTX) for
24 h antagonized the inhibition of VGCC currents by Vc1.1
(99.9  4.5% of control, n  11) (Fig. 6A,C). Together, these
results suggest that the mechanism by which Vc1.1 inhibits HVA
Ca2 channel currents involves a PTX-sensitive GPCR of the
Gi/o subfamily.
Nonreceptor tyrosine kinases have been implicated in voltage-
independent inhibition of N-type Ca2 channel currents initi-
ated by activation of GPCR pathways (Diverse´-Pierluissi et al.,
1997; Strock and Diverse´-Pierluissi, 2004; Raingo et al., 2007).
We therefore tested the ability of Vc1.1 to inhibit HVA Ca2
channel currents when a selective peptide inhibitor of pp60c-src
tyrosine kinase (Roussel et al., 1991) (100M)was included in the
intracellular recording solution. Vc1.1 had no effect on HVA
Ca2 channel currents in the presence of the pp60c-src peptide
(101.39 6.9% of control, n 10) (Fig. 6B,C).
Vc1.1 inhibits HVA Ca2 channel currents in DRG neurons
via GABAB receptor
To investigate further the identity of the primary target for Vc1.1,
a number of different receptor antagonists were tested for their
ability to antagonize the effect of Vc1.1 (Table 1). Antagonists of
neuronal nAChRs,mecamylamine and hexamethonium, and de-
sensitizing concentrations of ACh were bath applied 5 min
before application of Vc1.1 and in all cases failed to antagonize
the inhibition of N-type VGCC currents in DRG neurons by
Vc1.1. Similarly, the muscarinic acetylcholine receptor antago-
nist, atropine, the 1- and 2-adrenergic receptor antagonists,
prazosin and yohimbine, respectively, the -opioid receptor an-
tagonist, naloxone, and the GABAA receptor antagonist, bicucul-
line, all failed to antagonize the effect of Vc1.1 in the majority of
cells tested.
Numerous studies have shown that activation of GABAB re-
ceptors leads to inhibition of N-type Ca2 channel currents in
central and peripheral neurons (Menon-Johansson et al., 1993;
Guyon and Leresche, 1995; Fujikawa et al., 1997; Harayama et al.,
1998; Richman et al., 2005; Castro et al., 2007; Raingo et al.,
2007), but conotoxins have not previously been contemplated to
act on this pathway. The inhibition of N-type Ca2 channel cur-
rents after activation of GABAB receptors has been shown to
occur in both a voltage-dependent and a voltage-independent
manner, to be PTX-sensitive, and to involve c-Src (Richman et
al., 2005; Raingo et al., 2007). Several GABAB receptor antago-
nists were tested for their ability to antagonize Vc1.1 inhibition of
HVA Ca2 channel currents in DRG neurons. Application of 1
M Vc1.1 in the presence of the GABAB receptor antagonists
phaclofen (50 M) and CGP55485 (1 M) did not significantly
reduce the HVA Ca2 channel current in DRG neurons [95.5
4.4% (n 9 and 93.2 4.5% (n 14) of control, respectively]
(Fig. 7A,B). RgIA (100 nM) also failed to inhibit HVA Ca2
channel current in the presence of CGP55485 (92.5  3.5% of
control, n  5) (data not shown). Together, these data indicate
that Vc1.1 and Rg1A inhibit HVA Ca2 channel currents via
activation of the GABAB receptor in DRG neurons.
The GABAB receptor agonist baclofen has previously been
shown to inhibit HVA Ca2 channel currents in neonatal rat
DRG neurons (Dolphin and Scott, 1987, 1990; Menon-
Johansson et al., 1993; Fujikawa et al., 1997). We examined
whether the effects of Vc1.1 and baclofen were additive in inhi-
bition of the HVA Ca2 channel current. The inhibition pro-
duced after addition of 10–30 M baclofen (63.6  10.6% of
Figure 6. Vc1.1 inhibition of N-type calcium channel currents is mediated by G-protein-
coupled receptor and tyrosine kinase activation. A(i), Superimposed traces in the absence (a)
and presence (b) of 1 M Vc1.1 in cells incubated overnight in PTX (3 g/ml). Cells were
recorded under continual perfusion of PTX (200 ng/ml). (ii), Corresponding time course. B(i),
Superimposed traces in the absence (a) and presence (b) of Vc1.1 (1M) in cells recorded with
pp60c-src peptide (521-533) inhibitory peptide (100M) included in the recording pipette. (ii),
Corresponding time course. C, Bar graph of relative inhibition of HVA calcium channel currents
by Vc1.1 (1M) in regular recording solution (GTP), when a prepulse to80 mV (PP) was
applied 10 ms before the test pulse, when GTP was replaced with GDPS, after overnight
incubation in PTX, or when pp60c-src inhibitory peptide was included in the pipette recording
solution. ***p 0.0001 comparedwith control. Numbers in parentheses reflect the number of
cells.
Table 1. Receptor antagonists tested for reversal of the inhibition of N-type
calcium channel currents by-conotoxin Vc1.1
Antagonist (concentration) Target receptor
Antagonist of
Vc1.1 inhibition
Percentage inhibition
of IBa by Vc1.1 (n)
Mecamylamine (3M) nAChR  29.2 8.6 (3)
ACh (100M) nAChR  28.4 4.5 (7)
Atropine (1M) mAChR  27.2 10.4 (4)
Prazosin (10M) 1-Adrenergic  41.3 4.8 (3)
Yohimbine (10M) 2-Adrenergic  35.8 11.5 (3)
Naloxone (10M) -Opioid  50.1 12.4 (3)
Bicuculline (30M) GABAA  32.9 7.0 (10)
Phaclofen (50M) GABAB  4.6 4.4 (9)
CGP 55845 (1M) GABAB  6.8 4.5 (14)
CGP 54626 (1M) GABAB  7.4 2.3 (4)
, Reversal of Vc1.1 inhibition;, no effect; mAChR, muscarinic acetylcholine receptor.
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control, n 4) was not significantly greater than that produced
by 100 nM Vc1.1 alone (61.2  15.9% of control, n  4) in the
same cells. Similarly, application of Vc1.1 (100 nM) after addition
of 30 M baclofen did not further inhibit HVA Ba2 current
amplitude (63.6  7.2% of control, n  5) compared with ba-
clofen alone (64.6 6.6% of control, n 5) (Fig. 7C). Under the
present recording conditions (150 ms depolarizing pulse to10
mV applied at a frequency of 0.05 Hz), the time to maximum
inhibition (9.3 1.2min) and reversal (	5% after 10min wash-
out) by 30 M baclofen (n  11) was significantly slower than
when the depolarizing pulse was shortened to 15 ms or the fre-
quency of depolarization was increased to 0.1 Hz (time to maxi-
mum inhibition occurred in 2.8 0.9 min and complete recov-
ery within 5 min after washout of baclofen, n 5).
In subsequent experiments, we observed that in70% of oo-
cytes expressing recombinant CaV2.2 (N-type) but not CaV2.1
(P/Q-type), CaV2.3 (R-type), or CaV1.2 (L-type) calcium chan-
nels, application of baclofen (100 M) inhibited Ba2 currents
(supplemental Fig. 1, available at www.jneurosci.org as supple-
mental material). We therefore tested the effect of -conotoxins
Vc1.1 and Rg1A in these oocytes. Both Vc1.1 and Rg1A inhibited
Ba2 currents through recombinant CaV2.2 channels in
baclofen-responding oocytes (n 28). Preincubation of oocytes
with the selective GABAB receptor antagonist CGP55845 (1 M)
abolished the inhibition of Ba2 currents observedwith 1MVc1.1
(n  4) (supplemental Fig. 2, available at www.jneurosci.org
as supplemental material).
Discussion
To date, the -conotoxins have been classified as competitive
nAChR antagonists (Dutton and Craik, 2001; Livett et al., 2006).
The present study is the first to identify the N-type calcium chan-
nel of mammalian DRG neurons as a target of the -conotoxins
Vc1.1 and RgIA. To the best of our knowledge, this study is also
the first to describe conotoxinmodulation of an ion channel via a
G-protein receptor-activated pathway.
Vc1.1 andRg1A are of great interest as analgesic drugs because
of their effectiveness in peripheral nerve-injured rats (Satkunan-
athan et al., 2005; Vincler et al., 2006) Although these peptides
have been shown to be potent antagonists of 910 nAChRs,
post-translationally modified analogs of Vc1.1, [P6O]Vc1.1, and
vc1a are ineffective in assays of neuropathic pain (Livett et al.,
2006; Nevin et al., 2007). However, they are equipotent to Vc1.1
as 910 nAChRs antagonists, indicating that this nAChR is not
the therapeutic target of Vc1.1 (Nevin et al., 2007).
N-type calcium channels are an appealing target of Vc1.1 be-
cause they are well known to play a central role in the detection
and transmission of nociceptive stimuli in DRG neurons (Altier
and Zamponi, 2004). Several studies have highlighted the impor-
tance of N-type calcium channels in neuropathic pain: N-type
1B channel knock-outmice have a decreased response to neuro-
pathic pain (Hatakeyama et al., 2001; Kim et al., 2001; Saegusa et
al., 2001), there is an upregulation of N-type 1B as well as 2
subunits in rat nerve injury models (Abe et al., 2002; Cizkova et
al., 2002; Yokoyama et al., 2003), and currently used treatments,
or treatments being developed, for pain relief include direct (-
conotoxinMVIIA, also known as Prialt) and indirect (morphine)
inhibitors of N-type channels (McGivern, 2006).
HVACa2 channel currents of rat DRGneurons include con-
tributions from N-, P/Q-, L-, and R-type calcium channels
(Scroggs and Fox, 1992). The present study indicates that Vc1.1
targets solely the N-type component of the whole-cell Ca2 cur-
rent, because it had no effect in the presence of the N-type Ca2
channel blockers,-conotoxins CVID andMVIIA. Vc1.1 inhibi-
tion of N-type Ca2 channel current was irreversible after wash-
out of up to 30 min, but subsequent cells patched from the same
coverslip were as sensitive to Vc1.1 as the initial cell exposed to
Vc1.1. This suggests that Vc1.1 inhibition of N-type current is
dependent on membrane depolarization. Consistent with this
hypothesis, Vc1.1 had no effect on HVA Ca2 currents in DRG
neuronswhen the duration of the depolarization pulse was short-
ened to one-tenth of its initial duration with the frequencymain-
tained at 0.05 Hz. Vc1.1 inhibition was only observed with this
short depolarizing pulse when the frequency was increased to 0.1
Hz.
DRG neurons have been shown to express a splice variant
CaV2.2 that differs at exon 37 (Bell et al., 2004) from the periph-
eral splice variant we expressed, but extensive studies reported
here indicate that the reason Vc1.1 is ineffective on recombinant
N-type Ca2 channels is that it is acting via a G-protein receptor-
activated pathway. Our results suggest that theGPCR responsible
is the GABAB receptor: first, Vc1.1 inhibition of N-type Ca
2
current was antagonized by selective GABAB receptor antago-
nists, and second, similar to previous studies of the GABAB re-
ceptor agonist baclofen in rat or chick DRG neurons (Dolphin
and Scott, 1987; Richman andDiverse´-Pierluissi, 2004; Raingo et
Figure 7. GABAB receptor activation mediates Vc1.1 inhibition of N-type calcium channel
currents in rat DRG neurons. A(i), Superimposed traces of depolarization-activated whole-cell
Ba 2 currents in the presence of the GABAB inhibitor phaclofen (50M) followed by applica-
tion of 100nMVc1.1. (ii), Corresponding time course. Numbers on theplot indicatewhichpoints
were used for sample traces in A(i). B(i), Superimposed traces of depolarization-activated
whole-cell Ba 2 currents in the presence of another GABAB inhibitor CGP55845 (1M) (a), in
the presence of CGP55845 and Vc1.1 (100 nM) (b), and in the presence of Vc1.1 alone (100 nM)
(c). (ii), Corresponding time course. Numbers on the plot indicate which points were used for
sample traces in B(i). C(i), Superimposed traces of depolarization-activated whole-cell Ba 2
currents in the absence (a), in the presence of the GABAB agonist baclofen (30M) (b), and in
the presence of 100 nM Vc1.1 (c). (ii), Corresponding time course. Numbers on the plot indicate
which points were used for sample traces in C(i).
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al., 2007), Vc1.1 inhibition of N-type Ca2 currents in rat DRG
neurons was antagonized when GTP was replaced in the patch
pipette with GDPS, when the cells were incubated overnight
with PTX, and when c-Src tyrosine kinase activity was inhibited.
Activation of the GABAB receptor has been shown to inhibit
N-type Ca2 channel current by voltage-dependent (relieved by
a strong depolarizing prepulse) and voltage-independent path-
ways, and to be readily reversible after washout of baclofen (Rich-
man and Diverse´-Pierluissi, 2004; Raingo et al., 2007). No relief
of Vc1.1 inhibition was observed after depolarizing prepulses to
80 mV. Although baclofen inhibition during prolonged depo-
larizations (150 ms, 0.05 Hz) was also irreversible, baclofen inhi-
bition of N-type Ca2 current during short depolarization pulses
(15 ms, 0.05 Hz) was rapidly reversible after washout of baclofen
(our unpublished observations). These results suggest that Vc1.1
does not inhibit the N-type current via the fast, G-mediated,
membrane-delimited, voltage-dependent pathway associated
with GABAB receptor activation. Rather, it activates a pathway
that remains to be fully elucidated but involves pp60c-src ty-
rosine kinase and leads to a maintained inhibition of the N-type
Ca2 channel current, possibly as a result of persistent binding of
Vc1.1 to the GABAB receptor. Alternatively Vc1.1 may interact
differently with the GABAB receptor than baclofen, which binds
to the venus fly trap motif of the GABAB1 subunit, leading to its
closure and activation of the receptor (for review, see Emson,
2007).
Vc1.1 was without effect on recombinant CaV2.1 (P/Q-type),
CaV1.2 (L-type), and CaV2.3 (R-type) channels expressed in Xe-
nopus oocytes. However, in subsequent experiments we found
that baclofen activation of endogenous GABAB receptors in
batches of Xenopus oocytes mediates inhibition of Ba2 current
through recombinant CaV2.2 (N-type) channels. In oocytes ex-
pressing endogenous GABAB receptors, -conotoxins Vc1.1 and
Rg1A also inhibit recombinant CaV2.2 channels via agonist acti-
vation of a GABAB receptor-signaling pathway in Xenopus oo-
cytes (Yang et al., 2001).
The characteristics of the G-protein-induced inhibition of
voltage-dependent N-type calcium channels by Vc1.1 and Rg1A
activation of GABAB receptors is reminiscent of the agonist-
induced internalization of N-type calcium channels observed in
rat DRG neurons (Altier et al., 2006) and embryonic chick DRG
neurons (Puckerin et al., 2006; Tombler et al., 2006). Prolonged
exposure of opioid receptor-like receptor 1 (ORL1) receptors to
the agonist nociceptin has been shown to trigger the internaliza-
tion of the ORL1 receptors and Cav2.2 channels coexpressed in
human embryonic kidney tsA-201 cells (Altier et al., 2006), which
is accompanied by a tonic inhibition of calcium entry. Baclofen, a
GABAB agonist, has also been shown to induce the rapid removal
of -conotoxin GVIA-sensitive (N-type) calcium channels from
the plasma membrane of DRG neurons (Tombler et al., 2006). A
mechanism proposed for the internalization of voltage-
dependent calcium channels involves the selective binding of
-arrestin 1 to the SNARE (soluble N-ethylmaleimide-sensitive
factor attachment protein receptor)-binding region of the cal-
cium channel whereby, on GABAB receptor activation, receptors
are recruited to the arrestin–channel complex and internalized
(Puckerin et al., 2006). Furthermore, -arrestins have been
shown to be required to target nonreceptor tyrosine kinase c-Src
to constitutively active G-protein-coupled -opioid receptors in
DRG neurons, resulting in their internalization (Walwyn et al.,
2007). It is likely, therefore, that -conotoxin activation of
GABAB receptors and the inhibition of N-type calcium channels
in DRG neurons is mediated by a mechanism similar to that
reported previously for internalization of GPCR–channel
complexes.
In conclusion, our results identify Cav2.2 as a target of the
analgesic -conotoxins Vc1.1 and Rg1A. We propose a novel
mechanism by which these -conotoxins modulate N-type cal-
cium channel currents in DRGneurons, that is, acting as agonists
via G-protein-coupled GABAB receptors. The activation of
GABAB receptors by agonists such as baclofen is well established
to produce antinociceptive and antiallodynic actions in chronic
pain models (Schuler et al., 2001; Bettler et al., 2004). Therefore,
the activation of GABAB receptors by Vc1.1 and Rg1A and sub-
sequent inhibition of Cav2.2 (N-type) channels is most likely the
mechanism mediating their analgesic properties, despite their
recently reported modulation, at lower efficacy, of the 910
nAChR (Vincler et al., 2006; Vincler and McIntosh, 2007).
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